Redeye provides an update in relation to RLS’ Q2 2023 report. The report did not include any major surprises in our view, with low sales and OPEX similar to previous quarters; however, the information provided by the company is still limited, creating concerns of the future. Due to the company’s future uncertainties, we have chosen to decrease our sales expectations, which renders an updated fair value range, including a new base case of SEK5.5 (7).

Read more and download the Research Update.

Follow companies at Redeye to receive the latest equity research within Life Science and Technology.

This is a press release from Redeye - Research Powered Investment Banking. www.redeye.se/

Attachments

RLS Global Q2 2023 - Uncertain future

© Modular Finance, source Nordic Press Releases